Melanoma Posts on Medivizor

Evaluating the long-term outcomes of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutated advanced melanoma.

Posted by Medivizor on Dec 31, 2022 in Melanoma | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of encorafenib (Braftovi) alone or in combination with binimetinib (Mektovi) or vemurafenib (Zelboraf) alone in patients with BRAF-mutated advanced melanoma. The data showed that the encorafenib plus binimetinib combination lead to long-term effectiveness and no new safety...

Evaluating the effectiveness and safety of different treatments given after surgery in patients with advanced melanoma.

Posted by Medivizor on Dec 4, 2022 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of different treatments given after surgery in patients with advanced melanoma. The data showed that nivolumab (Opdivo) plus ipilimumab (Yervoy) was the best treatment regimen in significantly improving overall survival and survival without cancer worsening in these patients. Some...

Evaluating the safety and effectiveness of tebentafusp in previously treated patients with advanced uveal melanoma

Posted by Medivizor on Oct 25, 2022 in Melanoma | 0 comments

In a nutshell The study evaluated the safety and effectiveness of tebentafusp (Kimmtrak) in patients with metastatic uveal melanoma who had received previous treatments. The study found that tebentafusp had promising effectiveness and a good safety profile in these patients. Some background Uveal melanoma is a rare and aggressive eye tumor....

Comparing the effectiveness and safety of immune checkpoint inhibitors between randomized and real-world studies in patients with advanced NSCLC or melanoma.

Posted by Medivizor on Oct 7, 2022 in Melanoma | 0 comments

In a nutshell This study compared the effectiveness and safety of immune checkpoint inhibitors (ICIs) between randomized and real-world studies in patients with advanced non-small cell lung cancer (NSCLC) or melanoma. The data showed that ICIs were similarly effective and safe in both randomized and real-world studies for these patients. Some background...

Evaluating the effectiveness and safety of pembrolizumab given after surgery in patients with stage II melanoma.

Posted by Medivizor on Sep 30, 2022 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of pembrolizumab (Keytruda) given after surgery in patients with stage II melanoma. The data showed that pembrolizumab given after surgery for up to 1 year significantly reduced the risk of cancer recurrence or death in these patients. Some background Melanoma is one of the most...

Evaluating treatment outcomes of fractionated stereotactic radiotherapy in patients with small and moderate-sized brain metastases.

$Evaluating treatment outcomes of fractionated stereotactic radiotherapy in patients with small and moderate-sized brain metastases.$

Posted by Medivizor on Sep 17, 2022 in Melanoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of fractionated stereotactic radiation therapy (FSRT) for patients with small and moderate-sized brain metastases (BM). The data showed that FSRT was safe and effective in patients with BM of any size with excellent local control. Some background Stereotactic radiosurgery (SRS) is...

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Posted by Medivizor on Sep 1, 2022 in Melanoma | 0 comments

In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the...

How effective is an immunomodulatory vaccine against PD-L1 /IDO in combination with nivolumab for the treatment of metastatic melanoma?

Posted by Medivizor on Jun 1, 2022 in Melanoma | 0 comments

In a nutshell The study aimed to evaluate the safety and effectiveness of an immunomodulatory IDO/PD-L1 targeting peptide vaccine (IO102/IO103) combined with nivolumab (Opdivo) in patients with metastatic melanoma (MM). The study concluded that the IO102/IO103 vaccine combined with nivolumab is safe and effective in these...

Investigating the benefit of frequent surveillance imaging on the survival outcomes in patients with resected stage III melanoma.

Posted by Medivizor on May 8, 2022 in Melanoma | 0 comments

In a nutshell This study investigated the benefit of frequent surveillance imaging on the survival outcomes in patients with resected stage III melanoma. The data showed that patients who underwent less frequent imaging (12-monthly) had better outcomes than those who underwent more frequent imaging (3- to 4-monthly). Some background Melanoma is a...

Vacations for Adult Cancer Patients: Update

Posted by Peigi Chace on Mar 4, 2022 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 2 comments

Two of our most popular previous blog posts described free vacation opportunities for adults with cancer. Given the uncertainty of the past two years, we thought it was time for an update. Here is a short list of organizations that have made it their mission to provide needed respite to those affected by cancer. Each has been verified to have...

Evaluating the risk of lung inflammation associated with immunotherapy in advanced melanoma.

Posted by Medivizor on Dec 31, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the risk of pneumonitis (inflammation of the lung tissue) associated with immune checkpoint inhibitors (ICIs) for the treatment of patients with advanced melanoma. The data showed that ICIs were associated with a higher risk of pneumonitis compared with conventional chemotherapy in patients with advanced melanoma. Some...

Evaluating the effectiveness and safety of immune checkpoint inhibitors in combination with radiotherapy in advanced melanoma.

Posted by Medivizor on Dec 19, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of immune checkpoint inhibitors (ICIs) in combination with palliative (treatment to relieve pain) radiotherapy (pRT) for the treatment of patients with advanced melanoma. The data showed that the addition of pRT to ICIs is effective and safe in these patients. Some background Melanoma is...

Melanoma Posts on Medivizor

Evaluating the long-term outcomes of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutated advanced melanoma.

Evaluating the effectiveness and safety of different treatments given after surgery in patients with advanced melanoma.

Evaluating the safety and effectiveness of tebentafusp in previously treated patients with advanced uveal melanoma

Comparing the effectiveness and safety of immune checkpoint inhibitors between randomized and real-world studies in patients with advanced NSCLC or melanoma.

Evaluating the effectiveness and safety of pembrolizumab given after surgery in patients with stage II melanoma.

Evaluating treatment outcomes of fractionated stereotactic radiotherapy in patients with small and moderate-sized brain metastases.

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

How effective is an immunomodulatory vaccine against PD-L1 /IDO in combination with nivolumab for the treatment of metastatic melanoma?

Investigating the benefit of frequent surveillance imaging on the survival outcomes in patients with resected stage III melanoma.

Vacations for Adult Cancer Patients: Update

Evaluating the risk of lung inflammation associated with immunotherapy in advanced melanoma.

Evaluating the effectiveness and safety of immune checkpoint inhibitors in combination with radiotherapy in advanced melanoma.

Categories

Recent Posts

Archives

Melanoma Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email